Literature DB >> 14967724

Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol.

Hwa Kyoung Shin1, Yong Ki Kim, Ki Young Kim, Jeong Hyun Lee, Ki Whan Hong.   

Abstract

BACKGROUND: Remnant lipoprotein particles (RLPs), products of lipolytic degradation of triglyceride-rich lipoprotein derived from VLDL, exert atherogenesis. In this study, we observed how RLPs induced cytotoxicity in human umbilical vein endothelial cells (HUVECs) and cilostazol prevented cell death. METHODS AND
RESULTS: RLPs were isolated from the plasma of hyperlipidemic patients by use of an immunoaffinity gel mixture of anti-apolipoprotein A-1 and anti-apolipoprotein B-100 monoclonal antibodies. RLPs (50 microg/mL) significantly increased superoxide formation in HUVECs associated with elevated gp91phox mRNA and protein expression and Rac1 translocation, accompanied by increased production of tumor necrosis factor (TNF)-alpha and interleukin-1beta, DNA fragmentation, and cell death. Cilostazol (1 to 100 micromol/L) significantly suppressed not only NAD(P)H oxidase-dependent superoxide production but also TNF-alpha and interleukin-1beta release and restored viability. RLPs activated a lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), which was not inhibited by cilostazol. Treatment of HUVECs with monoclonal antibody for LOX-1 attenuated RLP-mediated production of superoxide, TNF-alpha, and interleukin-1beta and DNA fragmentation.
CONCLUSIONS: RLPs stimulated NAD(P)H oxidase-dependent superoxide formation and induction of cytokines in HUVECs via activation of LOX-1, consequently leading to reduction in cell viability with DNA fragmentation, and cilostazol exerts a cell-protective effect by suppressing these variables.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14967724     DOI: 10.1161/01.CIR.0000117403.64398.53

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  55 in total

1.  LOX-1 deletion improves neutrophil responses, enhances bacterial clearance, and reduces lung injury in a murine polymicrobial sepsis model.

Authors:  Zhuang Wu; Tatsuya Sawamura; Anna K Kurdowska; Hong-Long Ji; Steven Idell; Jian Fu
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

2.  Cilostazol add-on therapy for celecoxib synergistically inhibits proinflammatory cytokines by activating IL-10 and SOCS3 in the synovial fibroblasts of patients with rheumatoid arthritis.

Authors:  Yi Sle Lee; Sang Yeob Lee; So Youn Park; Sung Won Lee; Ki Whan Hong; Chi Dae Kim
Journal:  Inflammopharmacology       Date:  2019-05-23       Impact factor: 4.473

Review 3.  The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk.

Authors:  Pratik B Sandesara; Salim S Virani; Sergio Fazio; Michael D Shapiro
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

4.  HO-1 Induced by Cilostazol Protects Against TNF-α-associated Cytotoxicity via a PPAR-γ-dependent Pathway in Human Endothelial Cells.

Authors:  So Youn Park; Jin Ung Bae; Ki Whan Hong; Chi Dae Kim
Journal:  Korean J Physiol Pharmacol       Date:  2011-04-30       Impact factor: 2.016

Review 5.  The role of hypertriglyceridemia in atherosclerosis.

Authors:  Ngoc-Anh Le; Mary F Walter
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.113

6.  Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation.

Authors:  Limin Wang; Rajan Gill; Theresa L Pedersen; Laura J Higgins; John W Newman; John C Rutledge
Journal:  J Lipid Res       Date:  2008-09-23       Impact factor: 5.922

7.  Synergistic efficacy of concurrent treatment with cilostazol and probucol on the suppression of reactive oxygen species and inflammatory markers in cultured human coronary artery endothelial cells.

Authors:  So Youn Park; Jeong Hyun Lee; Hwa Kyoung Shin; Chi Dae Kim; Won Suk Lee; Byung Yong Rhim; Yung Woo Shin; Ki Whan Hong
Journal:  Korean J Physiol Pharmacol       Date:  2008-08-31       Impact factor: 2.016

8.  Cilostazol Attenuates 4-hydroxynonenal-enhanced CD36 Expression on Murine Macrophages via Inhibition of NADPH Oxidase-derived Reactive Oxygen Species Production.

Authors:  Mi Ran Yun; Hye Mi Park; Kyo Won Seo; Chae Eun Kim; Jung Wook Yoon; Chi Dae Kim
Journal:  Korean J Physiol Pharmacol       Date:  2009-04-30       Impact factor: 2.016

9.  Suppression of PU.1-linked TLR4 expression by cilostazol with decrease of cytokine production in macrophages from patients with rheumatoid arthritis.

Authors:  S Y Park; S W Lee; S H Baek; C W Lee; W S Lee; B Y Rhim; K W Hong; C D Kim
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

10.  Human rhinovirus 1B exposure induces phosphatidylinositol 3-kinase-dependent airway inflammation in mice.

Authors:  Dawn C Newcomb; Umadevi S Sajjan; Deepti R Nagarkar; Qiong Wang; Suparna Nanua; Ying Zhou; Christina L McHenry; Kenneth T Hennrick; Wan C Tsai; J Kelley Bentley; Nicholas W Lukacs; Sebastian L Johnston; Marc B Hershenson
Journal:  Am J Respir Crit Care Med       Date:  2008-02-14       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.